rs386834170
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The ENST00000299155.10(AMN):c.208-2A>G variant causes a splice acceptor change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000037 in 1,596,518 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Consequence
ENST00000299155.10 splice_acceptor
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
AMN | NM_030943.4 | c.208-2A>G | splice_acceptor_variant | ENST00000299155.10 | NP_112205.2 | |||
AMN | XM_011537202.4 | c.46-2A>G | splice_acceptor_variant | XP_011535504.1 | ||||
AMN | XM_011537203.4 | c.46-2A>G | splice_acceptor_variant | XP_011535505.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
AMN | ENST00000299155.10 | c.208-2A>G | splice_acceptor_variant | 1 | NM_030943.4 | ENSP00000299155 | P1 | |||
AMN | ENST00000541086.5 | n.954-2A>G | splice_acceptor_variant, non_coding_transcript_variant | 2 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152106Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000369 AC: 8AN: 216688Hom.: 0 AF XY: 0.0000337 AC XY: 4AN XY: 118870
GnomAD4 exome AF: 0.0000395 AC: 57AN: 1444294Hom.: 0 Cov.: 32 AF XY: 0.0000390 AC XY: 28AN XY: 717322
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152224Hom.: 0 Cov.: 33 AF XY: 0.0000134 AC XY: 1AN XY: 74442
ClinVar
Submissions by phenotype
Imerslund-Grasbeck syndrome type 2 Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Nov 22, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Mar 25, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Jan 01, 2007 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | 3billion | Sep 01, 2022 | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.004%). Canonical splice site is predicted to alter splicing and result in a loss or disruption of normal protein function. Multiple pathogenic loss-of-function variants are reported downstream of the variant. The variant has been reported at least twice as pathogenic without evidence for the classification (ClinVar ID: VCV000056751). Therefore, this variant is classified as Pathogenic according to the recommendation of ACMG/AMP guideline. - |
Imerslund-Grasbeck syndrome Pathogenic:2Other:1
not provided, no classification provided | not provided | Inserm U 954, Faculté de Médecine de Nancy | - | - - |
Likely pathogenic, no assertion criteria provided | literature only | Juha Muilu Group; Institute for Molecular Medicine Finland (FIMM) | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 28, 2023 | This sequence change affects an acceptor splice site in intron 3 of the AMN gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in AMN are known to be pathogenic (PMID: 12590260, 22929189). This variant is present in population databases (rs386834170, gnomAD 0.006%). Disruption of this splice site has been observed in individuals with Imerslund-GraÃàsbeck Syndrome (PMID: 12590260, 22078000, 24044590, 32045704). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 56751). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. - |
Imerslund-Grasbeck syndrome type 1 Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Bioscientia Institut fuer Medizinische Diagnostik GmbH, Sonic Healthcare | Jan 21, 2020 | - - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2023 | AMN: PVS1, PM2, PM3 - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at